All In Biotech

Drug Trial Radar · NCT01743027

Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis

Phase 3, Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model

Last checked: Nov 19, 2026Latest source record: Aug 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 902 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

902

Actual

Start

Jan 2013

Primary completion

Jul 2013

Study completion Jul 2013

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Dec 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.

Conditions

  • Allergic Conjunctivitis

Interventions

  • AL-4943A ophthalmic solutionDrug

  • Olopatadine hydrochloride ophthalmic solution, 0.2%Drug

  • Olopatadine hydrochloride ophthalmic solution, 0.1%Drug

  • AL-4943A ophthalmic solution vehicleDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Ocular Itching at Onset of ActionTime frame: Day 14 (3, 5, and 7 minutes post-CAC)
  2. Mean Ocular Itching at 24 Hours Duration of ActionTime frame: Day 1 (3, 5, and 7 minutes post-CAC)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.